Millennial Lithium (CVE:ML) Stock Passes Below Fifty Day Moving Average of $1.62

Share on StockTwits

Millennial Lithium Corp (CVE:ML) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $1.62 and traded as low as $1.56. Millennial Lithium shares last traded at $1.56, with a volume of 7,500 shares trading hands.

Separately, Liberum Capital set a C$2.20 price target on shares of Millennial Lithium and gave the company a “buy” rating in a research report on Friday, June 7th.

The stock has a market capitalization of $130.45 million and a P/E ratio of -7.86.

COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/4380225/millennial-lithium-cveml-stock-passes-below-fifty-day-moving-average-of-1-62.html.

Millennial Lithium Company Profile (CVE:ML)

Millennial Lithium Corp. engages in the acquisition, exploration, and development of lithium mineral properties. It primarily holds 100% interest in the Pastos Grandes Lithium Project located in Salta Province, Argentina. The company was formerly known as Redhill Resources Corp. and changed its name to Millennial Lithium Corp.

Featured Article: Straddles

Receive News & Ratings for Millennial Lithium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Millennial Lithium and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Elastic  Rating Lowered to Sell at Zacks Investment Research
Elastic Rating Lowered to Sell at Zacks Investment Research
Diplomat Pharmacy  Stock Rating Lowered by Zacks Investment Research
Diplomat Pharmacy Stock Rating Lowered by Zacks Investment Research
Dicerna Pharmaceuticals  Rating Lowered to Sell at Zacks Investment Research
Dicerna Pharmaceuticals Rating Lowered to Sell at Zacks Investment Research
Eastgroup Properties  Rating Lowered to Hold at Zacks Investment Research
Eastgroup Properties Rating Lowered to Hold at Zacks Investment Research
Zacks Investment Research Upgrades NOW  to “Buy”
Zacks Investment Research Upgrades NOW to “Buy”
Zacks Investment Research Downgrades Endologix  to Hold
Zacks Investment Research Downgrades Endologix to Hold


© 2006-2019 Ticker Report